MedTrace Logo

Dose Escalation With SIB to Intraprostatic/Lymphatic GTV in High Risk Prostate Cancer

NCT01962324 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2024-03-01

No results posted yet for this study

Summary

A single arm phase 2 study to study the outcome of dose-escalation with simultaneous integrated boost to intraprostatic lesion and positive lymph nodes. Prostate cancer patients with high risk of lymph node metastasis or oligo positive nodes in true pelvic area can be included. The boost volumes will be outlined by usin PET-CT and MRI data. Our hypothesis is that we will have fewer relapses in this very high risk patient group compared to matched historical controls with acceptable side effects.

Conditions

  • Prostatic Neoplasms
  • Lymphatic Metastasis

Interventions

RADIATION

SIB Dose-Escalation Radiotherapy

Sponsors & Collaborators

  • Umeå University

    lead OTHER

Principal Investigators

  • Camilla Thellenberg Karlsson, MD · Umea University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2023-05-09
Completion
2023-05-09

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01962324 on ClinicalTrials.gov